09:45 AM EST, 03/07/2024 (MT Newswires) -- Cigna Group ( CI ) said Thursday that it continues to expect 2024 adjusted earnings of at least $28.25 per diluted share and adjusted revenue of at least $235 billion.

The company said it now expects its long-term average annual adjusted EPS to grow 10% to 14%. That compares with its prior guidance of a 10% to 13% increase.

The company also said its pharmacy benefit management division, Evernorth Health Services, is launching a program aimed at controlling costs for new weight-loss medications. The program, known as GLP-1, is expected to support clients in managing expenses related to drugs mimicking the GLP-1 hormone, which regulates blood sugar and appetite, Cigna ( CI ) added.

Evernorth Health Services also plans to make a Humira biosimilar available at no cost to eligible Accredo patients, the company said.

Price: 345.81, Change: +5.98, Percent Change: +1.76